Matthew Kurian: DESTINY-Breast09 may change the landscape of first-line treatment for HER2+ MBC
Matthew Kurian, Physician at St. Elizabeth Healthcare and Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn by Jame Abraham, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic, adding:
“I share Jame Abraham, M.D. FACP’s enthusiasm! DESTINY-Breast09 may change the landscape of first-line treatment for HER2+ metastatic breast cancer in over a decade!
AstraZeneca and Daiichi Sankyo just announced that ENHERTU (trastuzumab deruxtecan) + pertuzumab significantly improved PFS over the current THP standard (taxane + trastuzumab + pertuzumab) in the first-line setting.
Full data coming soon at an upcoming meeting!”
Quoting Jame Abraham’s post:
“Exciting news from AZ Press Release – DESTINY 09! The data shows significant improvement in PFS for Enhertu + Pertuzumab compared to THP in first-line MBC.
This could potentially be practice-changing once we have all the data available. Stay tuned for more updates!”
More posts featuring Matthew Kurian and Jame Abraham.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023